These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32534258)

  • 1. Inhibition of prolyl hydroxylases increases hepatic insulin and decreases glucagon sensitivity by an HIF-2α-dependent mechanism.
    Riopel M; Moon JS; Bandyopadhyay GK; You S; Lam K; Liu X; Kisseleva T; Brenner D; Lee YS
    Mol Metab; 2020 Nov; 41():101039. PubMed ID: 32534258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes.
    Taniguchi CM; Finger EC; Krieg AJ; Wu C; Diep AN; LaGory EL; Wei K; McGinnis LM; Yuan J; Kuo CJ; Giaccia AJ
    Nat Med; 2013 Oct; 19(10):1325-30. PubMed ID: 24037093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PHD3 regulates glucose metabolism by suppressing stress-induced signalling and optimising gluconeogenesis and insulin signalling in hepatocytes.
    Yano H; Sakai M; Matsukawa T; Yagi T; Naganuma T; Mitsushima M; Iida S; Inaba Y; Inoue H; Unoki-Kubota H; Kaburagi Y; Asahara SI; Kido Y; Minami S; Kasuga M; Matsumoto M
    Sci Rep; 2018 Sep; 8(1):14290. PubMed ID: 30250231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
    Schley G; Klanke B; Kalucka J; Schatz V; Daniel C; Mayer M; Goppelt-Struebe M; Herrmann M; Thorsteinsdottir M; Palsson R; Beneke A; Katschinski DM; Burzlaff N; Eckardt KU; Weidemann A; Jantsch J; Willam C
    Kidney Int; 2019 Aug; 96(2):378-396. PubMed ID: 31146971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition.
    Wei K; Piecewicz SM; McGinnis LM; Taniguchi CM; Wiegand SJ; Anderson K; Chan CW; Mulligan KX; Kuo D; Yuan J; Vallon M; Morton L; Lefai E; Simon MC; Maher JJ; Mithieux G; Rajas F; Annes J; McGuinness OP; Thurston G; Giaccia AJ; Kuo CJ
    Nat Med; 2013 Oct; 19(10):1331-1337. PubMed ID: 24037094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation.
    Lee YS; Riopel M; Cabrales P; Bandyopadhyay GK
    Sci Adv; 2019 Jul; 5(7):eaaw4176. PubMed ID: 31281892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.
    Sugahara M; Tanaka S; Tanaka T; Saito H; Ishimoto Y; Wakashima T; Ueda M; Fukui K; Shimizu A; Inagi R; Yamauchi T; Kadowaki T; Nangaku M
    J Am Soc Nephrol; 2020 Mar; 31(3):560-577. PubMed ID: 31996409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of oxygen-sensing prolyl hydroxylases increases lipid accumulation in human primary tubular epithelial cells without inducing ER stress.
    Schley G; Grampp S; Goppelt-Struebe M
    Cell Tissue Res; 2020 Jul; 381(1):125-140. PubMed ID: 32189058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis.
    Keely S; Campbell EL; Baird AW; Hansbro PM; Shalwitz RA; Kotsakis A; McNamee EN; Eltzschig HK; Kominsky DJ; Colgan SP
    Mucosal Immunol; 2014 Jan; 7(1):114-23. PubMed ID: 23695513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIF2α Is an Essential Molecular Brake for Postprandial Hepatic Glucagon Response Independent of Insulin Signaling.
    Ramakrishnan SK; Zhang H; Takahashi S; Centofanti B; Periyasamy S; Weisz K; Chen Z; Uhler MD; Rui L; Gonzalez FJ; Shah YM
    Cell Metab; 2016 Mar; 23(3):505-16. PubMed ID: 26853750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver.
    Kato S; Ochiai N; Takano H; Io F; Takayama N; Koretsune H; Kunioka EI; Uchida S; Yamamoto K
    J Pharmacol Exp Ther; 2019 Dec; 371(3):675-683. PubMed ID: 31585986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-Inducible Factor Prolyl 4-Hydroxylase-2 Inhibition Protects Against Development of Atherosclerosis.
    Rahtu-Korpela L; Määttä J; Dimova EY; Hörkkö S; Gylling H; Walkinshaw G; Hakkola J; Kivirikko KI; Myllyharju J; Serpi R; Koivunen P
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):608-17. PubMed ID: 26848160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoform-specific Roles of Prolyl Hydroxylases in the Regulation of Pancreatic β-Cell Function.
    Hoang M; Jentz E; Janssen SM; Nasteska D; Cuozzo F; Hodson DJ; Tupling AR; Fong GH; Joseph JW
    Endocrinology; 2022 Jan; 163(1):. PubMed ID: 34718519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage HIF-2α ameliorates adipose tissue inflammation and insulin resistance in obesity.
    Choe SS; Shin KC; Ka S; Lee YK; Chun JS; Kim JB
    Diabetes; 2014 Oct; 63(10):3359-71. PubMed ID: 24947359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of HIF-2α in pancreatic β cells does not alter glucose homeostasis.
    Brunt JJ; Shi SY; Schroer SA; Sivasubramaniyam T; Cai EP; Woo M
    Islets; 2014; 6(5-6):e1006075. PubMed ID: 25833250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of miR-145-5p Causes Ceruloplasmin Interference with PHD-Iron Axis and HIF-2α Stabilization in Lung Adenocarcinoma-Mediated Angiogenesis.
    Tsai YM; Wu KL; Chang YY; Chang WA; Huang YC; Jian SF; Tsai PH; Lin YS; Chong IW; Hung JY; Hsu YL
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia inhibits TNF-α-induced TSLP expression in keratinocytes.
    Tashiro N; Segawa R; Tobita R; Asakawa S; Mizuno N; Hiratsuka M; Hirasawa N
    PLoS One; 2019; 14(11):e0224705. PubMed ID: 31682627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
    Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
    Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hypoxia-inducible factor pathway, prolyl hydroxylase domain protein inhibitors, and their roles in bone repair and regeneration.
    Fan L; Li J; Yu Z; Dang X; Wang K
    Biomed Res Int; 2014; 2014():239356. PubMed ID: 24895555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A patent review on hypoxia-inducible factor (HIF) modulators (2021-2023).
    Liu J; Gao Y; Zhang X
    Expert Opin Ther Pat; 2024 Aug; 34(8):651-664. PubMed ID: 38874005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.